Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Director Sells $1,093,425.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 7,500 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $145.79, for a total transaction of $1,093,425.00. Following the completion of the transaction, the director directly owned 10,386 shares in the company, valued at $1,514,174.94. The trade was a 41.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $159.76 on Friday. The stock has a market cap of $16.17 billion, a PE ratio of 23.70, a P/E/G ratio of 0.74 and a beta of 0.36. The firm has a 50-day moving average of $147.04 and a 200-day moving average of $147.90. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. Neurocrine Biosciences’s quarterly revenue was up 41.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.04 EPS. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 7.66 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Mizuho raised Neurocrine Biosciences to a “hold” rating in a research report on Wednesday, September 16th. Wall Street Zen cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Sunday, August 9th. Stifel Nicolaus boosted their price target on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Wells Fargo & Company upped their price objective on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, UBS Group lowered their price objective on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $202.32.

Institutional Trading of Neurocrine Biosciences

Institutional investors have recently bought and sold shares of the business. Fifth Third Bancorp increased its holdings in shares of Neurocrine Biosciences by 6.6% during the third quarter. Fifth Third Bancorp now owns 32,218 shares of the company’s stock worth $4,570,000 after purchasing an additional 2,001 shares during the period. New Mexico Educational Retirement Board raised its position in shares of Neurocrine Biosciences by 6.6% in the third quarter. New Mexico Educational Retirement Board now owns 21,000 shares of the company’s stock valued at $2,979,000 after buying an additional 1,300 shares in the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of Neurocrine Biosciences by 2.2% in the third quarter. Maryland State Retirement & Pension System now owns 5,714 shares of the company’s stock valued at $810,000 after buying an additional 123 shares during the period. Jacobi Capital Management LLC bought a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $42,000. Finally, Philadelphia Trust Co. grew its position in Neurocrine Biosciences by 0.4% during the third quarter. Philadelphia Trust Co. now owns 30,270 shares of the company’s stock worth $4,293,000 after buying an additional 135 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported third-quarter revenue of $1.12 billion, up 41% year over year and above estimates, with EPS of $3.29 versus a $1.91 consensus. The company also raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, reinforcing the growth case for its leading product. Q3 results and outlook
• Positive Sentiment: New survey findings showed fewer work or school disruptions among adults with tardive dyskinesia after starting INGREZZA: the share reporting disruptions fell from 57% to 21%, and average missed days declined from 5.6 to 2.0 per month. The results may bolster confidence in the treatment’s patient benefits. INGREZZA survey findings
• Positive Sentiment: Analysts raised price targets following the earnings report, including Morgan Stanley, Canaccord Genuity, RBC and Piper Sandler. Guggenheim also lifted its target to $224 and maintained a Buy rating, adding to the supportive analyst backdrop. Guggenheim rating
• Neutral Sentiment: After a sharp post-earnings advance, some investors may be taking profits, which could weigh on the shares despite the strong operating update. A director’s sale of 300 shares was made under a pre-arranged trading plan and appears small relative to his remaining holdings.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, risks that could complicate the expected value from the deal. Soleno acquisition risks

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.